Hypertension affects the majority of patients with chronic kidney disease (CKD) and increases the risk of cardiovascular disease, end-stage renal disease and mortality. Previously, many hypertension guidelines have suggested blood pressure targets in patients with CKD. Recently, the American College of Cardiology/American Heart Association 2017 Guideline for Hypertension suggests a new definition for hypertension and therapeutic targets, which were equally applicated to patients with CKD. These changes reflect the results of the Systolic Blood Pressure Intervention Trial (SPRINT) study, but the renal outcome of intensive blood pressure control was not good. Furthermore, the majority of hypertension guidelines including those of the Korean Society of Hypertension and the European Society of Hypertension have retained the traditional definition. Herein, we intend to analyze in detail the effect of intensive blood pressure control on kidney through the post-hoc analyses of the SPRINT study.
Blood Pressure ; Cardiovascular Diseases ; Diagnosis ; Heart ; Humans ; Hypertension ; Kidney ; Kidney Failure, Chronic ; Mortality ; Renal Insufficiency, Chronic

Diabetic kidney disease is a microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease resulting in renal replacement therapy. Approximately 30% to 40% of diabetic patients have diabetic kidney disease, which contributes to a significant increase in morbidity and mortality. Microalbuminuria is considered the gold standard for diabetic kidney disease diagnosis; however, its predictive value is restricted. Although blood glucose control, blood pressure control, and angiotensin converting enzyme inhibitors have been the primary treatment strategies, there are no definitive treatment modalities capable of inhibiting the progression of kidney dysfunction in these patients. This study was undertaken to answer seven questions regarding the various aspects of diabetic kidney disease. Why does it develop? what kind of factors affect its development? How is it diagnosed? What are its possible biomarkers? When is a kidney biopsy necessary? What are the preventive and therapeutic options? And what are the novel treatments?
Angiotensin-Converting Enzyme Inhibitors ; Biomarkers ; Biopsy ; Blood Glucose ; Blood Pressure ; Diabetes Mellitus ; Diabetic Nephropathies ; Diagnosis ; Humans ; Kidney ; Kidney Failure, Chronic ; Mortality ; Renal Replacement Therapy

BACKGROUND AND OBJECTIVES: Cardiovascular disease is a leading cause of death in patients on long-term dialysis and cardiac mortality decreases after renal transplantation. The aim of this study was to investigate the effects of successful renal transplantation on cardiac structure and function assessed by echocardiography. MATERIAL AND METHOD: Eighteen adult chronic renal failure patients who were taken renal transplantation in our hospital were included. They were submitted to two echocardiographic evaluations at preoperative time and postoperative time (mean: 23months). RESULTS: At the time of transplantation, 18 patients had undergone hemodialysis through a fistula (mean: 44months). At postoperative follow up, blood urea nitrogen/creatinine were decreased and mean hemoglobin level was increased. And systolic/diastolic blood pressure were decreased. Left ventricular mass index, left ventricular posterior wall thickness and septal wall thickness were decreased and ejection fraction was increased by echocardiography. Diastolic function did not improve. Hemodialysis duration and preoperative blood urea nitrogen/creatinine level affected ejection fraction change. CONCLUSION: We observed significantly decreased left ventricular mass index, increased ejection fraction after renal transplantation. We found that the patients who had been onlonger hemodialysis and higher preoperative blood urea nitrogen/creatinine level showed marked improvement of ejection fraction buy echocardiography.
Adult ; Blood Pressure ; Cardiovascular Diseases ; Cause of Death ; Dialysis ; Echocardiography* ; Fistula ; Follow-Up Studies ; Humans ; Kidney Failure, Chronic ; Kidney Transplantation* ; Mortality ; Renal Dialysis ; Urea

BACKGROUND: Mortality and morbidity of the patients with chronic renal failure frequently related to cardiovascular disease, especially to Hypertension. The present study was performed to assess the value of arnbulatory blood pressure(ABP) monitoring in determining the adequacy of blood pressure(BP) control, and its relationship to echocardiographic findings in hemodialysis (HD) patients. SUBJECT AND METHODS: Twenty adult patients who had been on regular hemodialysis treatment for median duration of 23 rnonths were studied. 24 hour ABP monitoring was performed using a non-invasive ABP monitor. All of the study population were non diabetic. Casual BP (CBP) was defined as the average of two measurements obtained at two HD sessions, one preceding and the one following the ABP recordings, and was calculated for both the predialysis and postdialysis phases. Cardiac echocardiography was performed in each patient to determine interventricular septal thickness(IVS), left ventricular posterior wall thickness(LVPW), left ventricular fractional shortening(FS), and left ventricular mass index(LVMI). RESULTS: 1) 17(85%) of patients showed left ventricular hypertrophy in echocardiography. LVMI was positively correlated with systolic BP load(r=0.45, p<0.05). But, the correlation between LVMI and diastolic BP load was not statistically significant. 2) IVS shoved positive correlation to 24hr systolic and diastolic blood pressure load, but LVPW did not show correlation to any subset of 24h-ABP monitoring data except daytime sysrolic BP load. 3) LVMI showed correlation to day-time systolic BP load, but it did not show correlation to night-time BP load. 4) Casual BP did not show correlation to echocardiographic data. CONCLUSIONS: These results suggest that 24hr ABP monitoring is more useful and accurate method than CBP to determine the degree of LVH and control of blood pressure in hemo- dialysis patients with hyertension.
Adult ; Blood Pressure ; Blood Pressure Monitoring, Ambulatory* ; Cardiovascular Diseases ; Dialysis ; Echocardiography* ; Humans ; Hypertension ; Hypertrophy, Left Ventricular ; Kidney Failure, Chronic ; Mortality ; Renal Dialysis*

Adult ; Aged ; Alkaline Phosphatase ; blood ; Female ; Humans ; Kaplan-Meier Estimate ; Kidney Failure, Chronic ; blood ; mortality ; therapy ; Male ; Middle Aged ; Peritoneal Dialysis ; Retrospective Studies

PURPOSE: Cardiac troponin T (cTnT), a useful marker for diagnosing acute myocardial infarction (AMI) in the general population, is significantly higher than the usual cut-off value in many end-stage renal disease (ESRD) patients without clinically apparent evidence of AMI. The aim of this study was to evaluate the clinical usefulness of cTnT in ESRD patients with acute coronary syndrome (ACS). MATERIALS AND METHODS: Two hundred eighty-four ESRD patients with ACS were enrolled between March 2002 and February 2008. These patients were followed until death or June 2009. Medical records were reviewed retrospectively. The cut-off value of cTnT for AMI was evaluated using a receiver operating characteristic (ROC) curve. We calculated Kaplan-Meier survival curves, and potential outcome predictors were determined by Cox proportional hazard analysis. RESULTS: AMIs were diagnosed in 40 patients (14.1%). The area under the curve was 0.98 in the ROC curve (p<0.001; 95% CI, 0.95-1.00). The summation of sensitivity and specificity was highest at the initial cTnT value of 0.35 ng/mL (sensitivity, 0.95; specificity, 0.97). Survival analysis showed a statistically significant difference in all-cause and cardiovascular mortalities for the group with an initial cTnT > or =0.35 ng/mL compared to the other groups. Initial serum cTnT concentration was an independent predictor for mortality. CONCLUSION: Because ESRD patients with an initial cTnT concentration > or =0.35 ng/mL have a poor prognosis, it is suggested that urgent diagnosis and treatment be indicated in dialysis patients with ACS when the initial cTnT levels are > or =0.35 ng/mL.
Acute Coronary Syndrome/blood/complications/*diagnosis/mortality ; Aged ; Biological Markers/blood ; Female ; Humans ; Kidney Failure, Chronic/blood/complications/*diagnosis/mortality ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Sensitivity and Specificity ; Troponin T/*blood

BACKGROUND AND OBJECTIVE: In dialysis patients, the cardiovascular mortality is 10 to 20 times higher than that in the general population. The increased arterial stiffness in patients with end-stage renal disease (ESRD) is an independent predictor of all-cause mortality. The arterial stiffness and atherosclerotic markers were evaluated in patients with ESRD treated with and without hemodialysis (HD) or peritoneal dialysis (PD). SUCJECTS AND METHODS: 14 hemodialysis (mean dialysis duration 19.6 months), 14 peritoneal dialysis (mean dialysis duration 26.1 months) and 14 patients with ESRD prior to initiation of dialysis, and 27 age-sex matched controls were enrolled. The calculated central pulse pressure, plasma homocysteine, serum C-reactive protein, left ventricular mass index and aortic pulse wave velocity (PWV) were measured. RESULTS: Patients with ESRD treated with and without dialysis had greater increases in their arterial stiffness and advanced atherosclerosis compared with the controls. However, there was no difference in the arterial stiffness and atherosclerotic markers before and after the dialysis treatment, or in the dialysis modality (HD, PD) of patients with ESRD. In a multiple regression model, PWV in patients with ESRD was explained by the level of plasma homocysteine (beta=0.396;p=0.027). CONCLUSION: Atherosclerosis and arterial stiffness in patients with ESRD may not be affected by dialysis treatment or modality. In patients with ESRD, the level of plasma homocysteine is independently associated with arterial stiffness.
Atherosclerosis ; Blood Pressure ; C-Reactive Protein ; Dialysis* ; Homocysteine ; Humans ; Kidney Failure, Chronic* ; Mortality ; Peritoneal Dialysis ; Plasma ; Pulse Wave Analysis ; Renal Dialysis ; Renal Insufficiency ; Vascular Stiffness*

BACKGOUND: Vascular calcification is highly correlated with cardiovascular disease mortality, especially in patients with end-stage renal disease (ESRD). Recent experimental research has implicated osteoprotegerin (OPG) in medial arterial calcification. The present study aims to examine whether serum OPG level is associated with the extent of aortic calcification in hemodialysis patients. METHODS: We studied 57 ESRD patients (59.5+/-14.1 years) on maintenance hemodialysis. Serum OPG level was measured by enzyme-linked immunosorbent assay. Abdominal aortic calcific deposits index (AAC index) was analysed with lateral lumbar radiograms. Patients were classified into tertile groups according to their AAC index: group I (0, n= 18), group II (1-4, n=18) and group III (5-18, n=21). Brachial ankle pulse wave velocity (baPWV) was also measured. RESULTS: Serum OPG level was greater in patients with higher AAC index than in those with lower AAC index but it was not statistically significant (group I: 409.8+/-343.5 pg/mL, group II: 575.9+/-723.3 pg/mL and group III: 660.8+/-593.5 pg/mL, p=0.399). There was a trend that serum OPG level was positively associated with AAC index, but it was not statistically significant (r=0.089, p=0.511). Serum OPG level showed positive correlation with age and pulse pressure. AAC index positively related with age and baPWV. CONCLUSION: Serum OPG levels seems to be positively related to AAC index by lateral lumbar radiograms, but it was not statistically significant. We suggest more extended studies to determine that serum OPG is helpful clinical marker for the extent of vascular calcification in maintenance hemodialysis patients.
Ankle ; Arteriosclerosis ; Biomarkers ; Blood Pressure ; Cardiovascular Diseases ; Enzyme-Linked Immunosorbent Assay ; Humans ; Kidney Failure, Chronic ; Mortality ; Osteoporosis ; Osteoprotegerin* ; Pulse Wave Analysis ; Renal Dialysis* ; Vascular Calcification

BACKGROUND: The clinical importance of hypokalemia is likely underrecognized in Chinese dialysis patients, and whether its clinical effect was mediated by serum albumin is not fully elucidated. This study aimed to explore the association between serum potassium and mortality in dialysis patients of a Chinese nationwide multicenter cohort, taking albumin as a consideration. METHODS: This was a prospective nation-wide multicenter cohort study. Restricted cubic splines were used to test the linearity of serum potassium and relationships with all-cause (AC) and cardiovascular (CV) mortality and a subsequent two-line piecewise linear model was fitted to approach the nadir. A mediation analysis was performed to examine relations of albumin to potassium and mortalities. RESULTS: A total of 10,027 patients were included, of whom 6605 were peritoneal dialysis and 3422 were hemodialysis patients. In the overall population, the mean age was 51.7 ± 14.8 years, 55.3%(5546/10,027) were male, and the median dialysis vintage was 13.60 (4.70, 39.70) months. Baseline serum potassium was 4.30 ± 0.88 mmol/L. After a median follow-up period of 26.87 (14.77, 41.50) months, a U-shape was found between potassium and mortality, and a marked increase in risk at lower potassium but a moderate elevation in risk at higher potassium were observed. The nadir for AC mortality risk was estimated from piecewise linear models to be a potassium concentration of 4.0 mmol/L. Interestingly, the significance of the association between potassium and mortality was attenuated when albumin was introduced into the extended adjusted model. A subsequent significant mediation by albumin for potassium and AC and CV mortalities were found ( P < 0.001 for both), indicating that hypokalemia led to higher mortality mediated by low serum albumin, which was a surrogate of poor nutritional status and inflammation. CONCLUSIONS Associations between potassium and mortalities were U-shaped in the overall population. The nadir for AC mortality risk was at a potassium of 4.0 mmol/L. Serum albumin mediated the association between potassium and AC and CV mortalities.
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; East Asian People ; Hypokalemia/etiology* ; Kidney Failure, Chronic/mortality* ; Potassium/blood* ; Prospective Studies ; Renal Dialysis ; Serum Albumin/analysis*

PURPOSE: End stage renal disease caused by diabetic nephropathy is increasing throughout the world. In earlier years, the results of kidney transplantation in diabetics were not as good as those in non-diabetics and the presence of diabetes has been considered as contraindication at many centers. But the survival rate of diabetic patients treated with transplantation has improved in recent years. In this study we compared the results of kidney transplantation in diabetic patients group with those of non-diabetic patients group. METHODS: We reviewed our experience in a single center with 1,386 kidney transplantation patients in non-diabetic patients, compared with 31 kidney transplantation patients in diabetic patients. The clinical characteristics such as age, sex, duration of diabetes mellitus, serum albumin, blood urea nitrogen, hemoglobin, glycated hemoglobin, creatinine clearance, and morbidity were retrieved from medical charts. RESULTS: For diabetic transplantation patients one- and five year patient survival were 92.3% and 84%; for non-diabetic transplantation patients one- and five year patient survival were 98.7% and 93.4%. It showed statistically significant differences in patient survival between two groups. We analyzed graft survival in two ways. When all deaths were not censored, the graft survival rate of diabetic transplantation patients was significantly lower than that of non-diabetic transplantation patients: 80.6% vs 85.8% at 5 years and 27.3% vs 68.6% at 10 years (P=0.04). But the graft survival rate did not differ significantly between the diabetic and non-diabetic patients when deaths were censored: 95% vs 91.7% at 5years and 63.3% vs 79.5% at 10 years (P=0.96) In the analysis of risk factors affecting patient mortality, presence of DM and graft loss were associated with mortality and its odds ratios were 8.94 and 6.33 respectively. CONCLUSION: The overall patient survival and graft survival were significantly worse in the diabetic transplantation patient group than the non-diabetic transplantation patient group. But graft survival was not different between two groups when death was censored. This means that graft survival in diabetic transplantation group is not different actually with non- diabetic transplantation group when comorbidities are fully evaluated and treated before transplantation.
Blood Urea Nitrogen ; Comorbidity ; Creatinine ; Diabetes Mellitus ; Diabetic Nephropathies ; Graft Survival ; Hemoglobin A, Glycosylated ; Humans ; Kidney Failure, Chronic ; Kidney Transplantation* ; Kidney* ; Mortality ; Odds Ratio ; Risk Factors ; Serum Albumin ; Survival Rate ; Transplants